- $5.35bn
- $5.46bn
- $616.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.28 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -31.97% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.26 | ||
| Price to Tang. Book | 8.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.69 | ||
| EV to EBITDA | 44.24 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.56% | ||
| Return on Equity | 102.75% | ||
| Operating Margin | 20.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.69 | 2.79 | 233.66 | 329 | 616.29 | 900.75 | 1,140.93 | 426.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +101.63 | +1510.24 | -47.66 | +54.48 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Directors
- Michael Weiss CHM (55)
- Sean Power CFO (39)
- Laurence Charney LED (74)
- Yann Echelard IND (57)
- Kenneth Hoberman IND (56)
- Daniel Hume IND (54)
- William Kennedy IND (76)
- Sagar Lonial IND (54)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- May 18th, 1993
- Public Since
- December 14th, 1995
- No. of Shareholders
- 196
- No. of Employees
- 399
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 159,688,256
- Address
- 3020 Carrington Mill Blvd., Suite 475, MORRISVILLE, 27560-5435
- Web
- https://www.tgtherapeutics.com/
- Phone
- +1 3026587581
- Auditors
- KPMG LLP
Upcoming Events for TGTX
TG Therapeutics Inc Annual Shareholders Meeting
Q2 2026 TG Therapeutics Inc Earnings Release
Similar to TGTX
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the TG Therapeutics share price?
As of Today at 14:40 UTC, shares in TG Therapeutics are trading at $33.53. This share price information is delayed by 15 minutes.
How has the TG Therapeutics share price performed this year?
Shares in TG Therapeutics last closed at $33.53 and the price had moved by -15.8% over the past 365 days. In terms of relative price strength the TG Therapeutics share price has underperformed the S&P500 Index by -35.09% over the past year.
What are the analyst and broker recommendations for TG Therapeutics?
The overall consensus recommendation for TG Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TG Therapeutics dividend yield?
TG Therapeutics does not currently pay a dividend.
Does TG Therapeutics pay a dividend?
TG Therapeutics does not currently pay a dividend.
When does TG Therapeutics next pay dividends?
TG Therapeutics does not currently pay a dividend.
How do I buy TG Therapeutics shares?
To buy shares in TG Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TG Therapeutics?
As of the previous close price of $33.53, shares in TG Therapeutics had a market capitalisation of $5.35bn.
Where are TG Therapeutics shares listed?
Here are the trading details for TG Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TGTX
What kind of share is TG Therapeutics?
Based on an overall assessment of its quality, value and momentum TG Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TG Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in TG Therapeutics is $44.17. That is 31.73% above the last closing price of $33.53.
Analysts covering TG Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $1.45 for the next financial year.
Find out moreWhat is the trend in the TG Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TG Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -6.46%.
As of the last closing price of $33.53, shares in TG Therapeutics were trading +4.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TG Therapeutics PE Ratio?
The TG Therapeutics PE ratio based on its reported earnings over the past 12 months is 20.28. The shares last closed at $33.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TG Therapeutics?
TG Therapeutics' management team is headed by:
- Michael Weiss - CHM
- Sean Power - CFO
- Laurence Charney - LED
- Yann Echelard - IND
- Kenneth Hoberman - IND
- Daniel Hume - IND
- William Kennedy - IND
- Sagar Lonial - IND